- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03191617
Nutrition of Premature Infants With Human Breastmilk Fortifier (EFORT-LM)
March 27, 2019 updated by: Patricia Mena Nannig, NEOCOSUR
Nutrition of Premature Infants With Human Breastmilk Fortifier With Higher Protein Content and Long Chain Poli- Unsaturated Fatty Acids (LCPUFA)
The objective of the study is to compare two human milk fortifiers with different protein content and LCPUFA in a group of very low birth weight infants.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This study is a multi-center, third party-blinded, randomized, controlled, parallel- group, prospective trial comparing growth with a liquid human milk fortifier with higher protein content and LCPUFA and a control powdered human milk fortifier added to breast milk and fed to premature infants.
The trial will be conducted in 11 centers in Chile.
The enrollment period is expected to be approximately 18 months.
To allow for dropouts, approximately 160 participants will be randomized.
Study Type
Interventional
Enrollment (Anticipated)
160
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Daniela Masoli, MD
- Phone Number: 56-9-95453952
- Email: daniela.masoli@gmail.com
Study Locations
-
-
Metropolitana
-
Santiago, Metropolitana, Chile, 8330024
- Recruiting
- Pontificia Universidad Catolica de Chile
-
Contact:
- JOSE L TAPIA, MD
- Phone Number: 56-9-92318797
- Email: jlta@med.puc.cl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 days to 1 month (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Premature infant equal or under 31 weeks gestational age at birth
- Birth weight equal or under 1,250 g
- Predominantly fed breast milk (mother's milk or donor milk) on study day 0
- Appropriate birth weight for gestational age (AGA) - defined as birth weight between and inclusive of the 10th and 90th percentiles on the Fenton growth chart
- Singleton or twin birth (both twins do not need to qualify and be randomized into study)
- Birth weight is ≤1,000 g and participant is ≤ 40 days of age on study day 0
- Birth weight is above 1,000 g and participant is ≤ 30 days of age on study day 0
- Enteral intake of 80 mL/kg/d of unfortified breast milk on study day 0
- Anticipate mother's willingness to breast milk for at least 28 days from study day 0
- Signed informed consent obtained
Exclusion Criteria:
- History of underlying metabolic or chronic disease, congenital malformation, or any other condition which, in the opinion of the Investigator, is likely to interfere with: the ability of the participant to ingest food, normal growth and development of the participant, or the evaluation of the participant
- 5 minute APGAR score ≤ 4
- Major surgery that required general anesthesia prior to first day study (note: persistent ductus arterious ligation is allowed)
- Received pharmacologic doses of glucocorticoids during 3 consecutive days (72 hours) prior to or on day one of study (physiologic hydrocortisone administration up to 1.5 mg/kg/d is permitted)
- Ventilator-dependent and requiring ≥ 40% fraction of inspired oxygen (FiO2) on day one of study (ventilator dependent and requiring ≤ 40% FiO2 and/or nasal canula, and/or nasal continous positive airway pressure (CPAP) and/or oxygen hood is allowed)
- Grade III or IV bilateral intraventricular hemorrhage (IVH) prior to or on study day one
- Feeding intolerance to breast milk feedings on study day one
- Consumption of more than 3 feedings or 12 hours of continuous feeds of fortified breast milk prior to study day one
- Fluid restriction < 120 mL/kg/d
- History of creatinine >2.0 mg/dL 7 days prior to or on study day one
- Currently receiving or plan use of probiotics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Liquid human milk fortifier
Liquid human milk fortifier which has higher protein content and also LCPUFA
|
Fortification of breastmilk with liquid human milk fortifier in premature infants
Other Names:
|
Active Comparator: Powder human milk fortifier
Powder human milk fortifier with less protein content and no LCPUFA
|
Fortification of breastmilk with liquid human milk fortifier in premature infants
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight and linear growth
Time Frame: between entering study and 45 days in study or discharge, whatever first
|
Weight increase in g/K/day and knee-to-heel length increase in mm/weeks, measured in one scale (+-5 g) and one kneenometer (special device to measure longitude) (+- 1mm) by one person for each center between entering study and 45 days in study or discharge
|
between entering study and 45 days in study or discharge, whatever first
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare length of hospital- stay
Time Frame: days from the first day of study to discharge home , an average of 37 weeks of postconceptual age
|
days from the first day of study to discharge home ( weight is one criteria for discharge)
|
days from the first day of study to discharge home , an average of 37 weeks of postconceptual age
|
Compare feeding tolerance
Time Frame: Between entering study and 45 days in study or discharge, if discharge first
|
Daily record of residue, regurgitation and suspend of gastric feedings
|
Between entering study and 45 days in study or discharge, if discharge first
|
Compare incidence of main preterm morbidities: necrotizing enterocolitis, bronchopulmonary dysplasia, retinopathy of prematurity and sepsis
Time Frame: Between entering study and 45 days in study or discharge, if discharge is first
|
Incidence of necrotizing enterocolitis grade II or more, bronchopulmonary dysplasia as additional oxygen at 36 postconceptual weeks, retinopathy of prematurity with treatment and sepsis with positive hemoculture
|
Between entering study and 45 days in study or discharge, if discharge is first
|
Compare cost/benefits . The cost of use a fortificant and the benefit of growth velocity
Time Frame: Between entering study and 45 days in study or discharge, if discharge is first
|
compare cost of total amount of fortifier used compare with cost of number of days of hospitalization, number of days in neonatal intensive care unit in each group.
|
Between entering study and 45 days in study or discharge, if discharge is first
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Patricia Mena, MD, Hospital Sotero del Rio
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2015
Primary Completion (Anticipated)
August 1, 2019
Study Completion (Anticipated)
December 1, 2019
Study Registration Dates
First Submitted
November 19, 2015
First Submitted That Met QC Criteria
June 15, 2017
First Posted (Actual)
June 19, 2017
Study Record Updates
Last Update Posted (Actual)
March 28, 2019
Last Update Submitted That Met QC Criteria
March 27, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEOCOSUR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Growth Acceleration
-
University of California, DavisCompletedGrowth Acceleration | Growth RetardationUnited States
-
Société des Produits Nestlé (SPN)Completed
-
Bright Dairy & Food Co., LtdCompleted
-
Ethiopian Public Health InstituteWageningen University; Micronutrient InitiativeCompletedGrowth Acceleration | Infant MorbidityEthiopia
-
University of CopenhagenUniversity of Aarhus; Arla FoodsCompletedGrowth Acceleration | Growth; Stunting, NutritionalDenmark
-
Ege UniversityBuca Women Birth and Child Diseases HospitalCompletedGrowth Acceleration | Development, Infant | Breastfeeding, Exclusive | AttachmentTurkey
-
University of IcelandHarvard Medical School (HMS and HSDM); Massachusetts General Hospital; University...CompletedAdiposity | Body Composition, Beneficial | Growth Acceleration
-
Beni-Suef UniversityRecruitingAcceleration of Tooth MovementEgypt
-
Jordan University of Science and TechnologyCompletedPiezocision | Acceleration of Tooth Movement
-
Cairo UniversityRecruitingOrthodontics | Platelet-Rich Fibrin | AccelerationEgypt
Clinical Trials on Human milk fortifier
-
Abbott NutritionCompleted
-
Abbott NutritionCompleted
-
Augusta UniversityNeolac Inc dba Medolac LaboratoriesUnknownPremature Infant | Breast Milk ExpressionUnited States
-
Medical University of ViennaParacelsus Medical UniversityCompletedPreterm Infants | Weight Gain | Human Milk | Extremely Low Birth WeightAustria
-
The University of Texas Health Science Center at...Baylor College of Medicine; Columbia University; University of Oklahoma; University... and other collaboratorsCompletedCongenital Heart DefectUnited States
-
The Hospital for Sick ChildrenCompleted
-
Prolacta BioscienceCompleted